Spironolactone GFR Threshold
Do not use spironolactone when eGFR is ≤30 mL/min/1.73 m², and serum potassium must be <5.0 mEq/L before initiation. 1, 2
Clear Cutoff from Guidelines
The 2022 AHA/ACC/HFSA Heart Failure Guidelines establish an explicit threshold: eGFR >30 mL/min/1.73 m² is required for spironolactone use in heart failure patients 2. This represents a Class 1A recommendation—the strongest level of evidence and recommendation.
Dosing Adjustments Based on Renal Function
The approach differs based on kidney function:
- eGFR >50 mL/min/1.73 m²: Start 25 mg daily, may increase to 50 mg daily 3
- eGFR 31-49 mL/min/1.73 m²: Reduce dosing by half (consider 25 mg every other day) due to hyperkalemia risk 1, 3
- eGFR ≤30 mL/min/1.73 m²: Contraindicated—spironolactone and its metabolites are partially renally excreted, creating unacceptable safety concerns 1
Critical Safety Monitoring
Beyond the eGFR threshold, you must verify:
- Serum potassium <5.0 mEq/L before starting therapy 2
- Discontinue if potassium rises to ≥5.5 mEq/L to avoid life-threatening hyperkalemia 1
Monitor potassium and renal function at approximately 1 week, then 4 weeks, then every 6 months after initiation or dose changes, with more frequent testing if clinically unstable 1.
Evidence Supporting the Threshold
The landmark trials (RALES, EPHESUS, EMPHASIS-HF) that established spironolactone's mortality benefit systematically excluded patients with severe renal impairment 1. While research shows spironolactone can be used cautiously in CKD stages 3-4 with close monitoring 4, 5, the guideline threshold of eGFR >30 mL/min/1.73 m² reflects the balance between efficacy and the amplified risk of hyperkalemia and worsening renal function as kidney disease advances 5.
Common Pitfalls to Avoid
Do not continue spironolactone if eGFR drops below 30 mL/min/1.73 m² during treatment. Acute eGFR decreases are common after MRA initiation (occurring in 26-33% of patients) 6, but a modest dip doesn't automatically warrant discontinuation if eGFR remains >30 mL/min/1.73 m² and potassium stays controlled. However, crossing below the 30 mL/min/1.73 m² threshold requires stopping the medication.
Temporary holds are appropriate during acute illness causing dehydration, diarrhea, or when loop diuretics are interrupted 1. Reassess the entire medication regimen rather than reflexively restarting spironolactone without addressing the underlying cause of renal deterioration.
The FDA labeling reinforces this threshold, specifying that for heart failure, eGFR must be >30 mL/min/1.73 m² and recommending consideration of every-other-day dosing when eGFR is 30-50 mL/min/1.73 m² 3.